克隆性造血在射血分数保留的心力衰竭临床与实验研究中的作用
该研究在81例HFpEF患者和36例对照中采用超深度纠错测序检测克隆性造血(CH),发现HFpEF患者中TET2介导的CH富集(12%对0%,P=0.02)。CH与更严重的舒张功能障碍相关,且年龄≥70岁伴CH的HFpEF患者5年心血管住院风险增高(HR=5.06,P=0.042)。小鼠实验表明Tet2缺陷骨髓移植可加重HFpEF样特征。
要点
- HFpEF患者中TET2介导的CH较对照显著富集。
- CH与HFpEF患者更严重的舒张功能障碍独立相关。
- 年龄≥70岁伴CH的HFpEF患者5年心血管住院风险增加。
核心结论
- CH与HFpEF患者心功能恶化和预后不良相关。
- 小鼠Tet2介导的CH模型表现出更显著的HFpEF特征。
研究设计与样本
- 病例对照研究:81例HFpEF患者(平均年龄71±6岁,射血分数63±5%)和36例无HFpEF对照(平均年龄74±7岁,射血分数61.5±8%)。
- 采用20个候选CH驱动基因 panel 和0.5%变异等位基因频率 cutoff 的超深度纠错测序检测CH。
- 在59例HFpEF验证队列中评估CH。
- 小鼠实验:非清髓小鼠接受Tet2野生型或Tet2缺陷骨髓 adoptive transfer,后予高脂饮食/L-NAME联合处理诱导HFpEF特征。
主要发现
- HFpEF患者TET2介导的CH比例为12%,对照组为0%(P=0.02)。
- HFpEF伴CH患者较无CH患者E/e'更高(14.9对11.7,P=0.0096),E/A更高(1.69对0.89,P=0.0206)。
- 验证队列证实CH与舒张功能障碍加重相关。
- 年龄≥70岁伴CH的HFpEF患者5年心血管相关住院率的风险比为5.06(P=0.042)。
- 小鼠Tet2-CH模型较野生型加重心脏肥厚(心脏重量/胫骨长度、心肌细胞大小)、舒张功能障碍(E/e'和左室舒张末压)及心肌纤维化。
临床怎么用
- 对HFpEF患者,尤其年龄≥70岁者,可考虑检测CH以辅助风险分层。
- CH阳性HFpEF患者可能需更密切随访和强化管理以降低住院风险。
局限性
- CH检测基于20个候选基因 panel,可能遗漏其他驱动基因。
- 研究样本量较小,结论需更大规模队列验证。
- 小鼠模型采用特定诱导方式,与人类HFpEF病理生理存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the role of CH in the prognosis of HF with preserved ejection fraction (HFpEF) has been understudied. This study aimed to characterize CH in patients with HFpEF and elucidate its causal role in a murine model. METHODS: Using a panel of 20 candidate CH driver genes and a variant allele fraction cutoff of 0.5%, ultradeep error-corrected sequencing identified CH in a cohort of 81 patients with HFpEF (mean age, 71±6 years; ejection fraction, 63±5%) and 36 controls without a diagnosis of HFpEF (mean age, 74±7 years; ejection fraction, 61.5±8%). CH was also evaluated in a replication cohort of 59 individuals with HFpEF. RESULTS: Compared with controls, there was an enrichment of TET2-mediated CH in the HFpEF patient cohort (12% versus 0%, respectively; P=0.02). In the HFpEF cohort, patients with CH exhibited exacerbated diastolic dysfunction in terms of E/e' (14.9 versus 11.7, respectively; P=0.0096) and E/A (1.69 versus 0.89, respectively; P=0.0206) compared with those without CH. The association of CH with exacerbated diastolic dysfunction was corroborated in a validation cohort of individuals with HFpEF. In accordance, patients with HFpEF, an age ≥70 years, and CH exhibited worse prognosis in terms of 5-year cardiovascular-related hospitalization rate (hazard ratio, 5.06; P=0.042) compared with patients with HFpEF and an age ≥70 years without CH. To investigate the causal role of CH in HFpEF, nonconditioned mice underwent adoptive transfer with Tet2-wild-type or Tet2-deficient bone marrow and were subsequently subjected to a high-fat diet/L-NAME (Nω-nitro-l-arginine methyl ester) combination treatment to induce features of HFpEF. This model of Tet2-CH exacerbated cardiac hypertrophy by heart weight/tibia length and cardiomyocyte size, diastolic dysfunction by E/e' and left ventricular end-diastolic pressure, and cardiac fibrosis compared with the Tet2-wild-type condition. CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.
引用
- Cochran JD, Yura Y, Thel MC, et al. Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction. Circulation. 2023. PMID: 37681311. doi:10.1161/CIRCULATIONAHA.123.064170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。